Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/28/24
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent HighlightsPRNewsWire • 02/28/24
Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?Zacks Investment Research • 01/29/24
Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of GrowthPRNewsWire • 01/05/24
Avidity's stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone paymentsMarket Watch • 11/28/23
Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent HighlightsPRNewsWire • 11/08/23
Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle SocietyPRNewsWire • 09/26/23
Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical ProgramsPRNewsWire • 09/07/23
Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual ConferencePRNewsWire • 08/31/23
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/09/23
Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent HighlightsPRNewsWire • 08/08/23
Avidity Biosciences Joins with Patients, Caregivers and Healthcare Providers Globally to Support World Facioscapulohumeral Muscular Dystrophy (FSHD) DayPRNewsWire • 06/20/23
Avidity Biosciences Announces Upcoming Presentations at the 30th Annual FSHD Society International Research CongressPRNewsWire • 06/08/23
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/09/23
Avidity Biosciences Reports First Quarter 2023 Financial Results and Recent HighlightsPRNewsWire • 05/09/23
Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA™ Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1PRNewsWire • 04/27/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avidity Biosciences, Inc. - RNAPRNewsWire • 04/19/23
Avidity Biosciences Announces Upcoming Presentations at the 75th American Academy of Neurology Annual MeetingPRNewsWire • 04/17/23